相关实验视频

Updated: May 24, 2025

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

患有心脏性休克患者的ECPella 5+:改善结局的潜力

Nicoletta D'Ettore¹, Astrid Cardinale², Giulia Maj²

¹Department of Cardiology, San Giacomo Hospital, Novi Ligure, Alessandria, Italy.

Journal of cardiothoracic and vascular anesthesia

|February 28, 2025

概括

静脉动脉外体膜氧化 (VA-ECMO) 结合Impella 5+可能会改善心脏性休克患者的治疗结果. 与其他ECPella组合相比,这种ECPella 5+治疗显示出较低的死亡率,因此需要进一步调查.

科学领域:

心脏病学心脏病学
机械循环支持机械循环支持
关键护理医学关键护理医学

背景情况:

静脉动脉外体膜氧化 (VA-ECMO) 是心脏性休克 (CS) 的关键治疗方法.
将VA-ECMO与Impella (ECPella) 结合起来可以改善患者的治疗结果.
对于ECPella治疗中使用的不同Impella代的有限的比较数据存在.

研究的目的:

评估ECPella治疗的临床结果,特别是使用Impella 5+设备在心脏性休克患者中.
为了比较ECPella 5+与其他ECPella配置和当代患者队列的疗效.

主要方法:

在PubMed (2017年1月 - 2023年10月) 上发表的84项研究的系统综述,重点关注CS中的ECPella.
对24篇选定的文章进行了全面分析,以提取关于ECPella 5+使用和结果的数据.
与10名接受ECPella 5+治疗的患者队列 (2022年1月至2023年5月) 的研究结果进行比较.

主要成果:

从2023年开始,ECPella 5+的使用量有所增加,在研究中占ECPella配置的50%以上.
对于ECPella 5+的死亡率为33% (在5项研究中),而所有ECPella组合的死亡率为49%.
当代ECPella 5+队列中观察到的死亡率为30%,与已发表的数据保持一致.

结论:

伊佩拉5+可能在改善心脏性休克ECPella治疗的患者的治疗结果方面提供进一步的好处.
目前的发现受到小样本大小和数据描述性质的限制.
需要进行更大规模的前性研究来证实这些益处,并评估对并发症率和本地心脏恢复的影响.

关键词:

在 ECPella 里面.心脏发生的冲击是心脏发生的冲击.机械循环支持机械循环支持死亡率死亡率

更多相关视频

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

相关概念视频

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...